Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480769 | 1.00 | RAB9A (0.41) | RAB9AROCK2ALDH1A1HTTKDM4E | |
| SCHEMBL6480869 | 0.91 | BACE1 (0.40) | ALDH1A1BACE1 | |
| SCHEMBL6480871 | 0.91 | BACE1 (0.40) | ALDH1A1BACE1 | |
| SCHEMBL6478954 | 0.90 | KMT2A (0.41) | ALDH1A1HTTBACE1 | |
| SCHEMBL6491686 | 0.87 | PTPN1 (0.40) | ALDH1A1BACE1 | |
| SCHEMBL6488382 | 0.86 | MEN1 (0.47) | RAB9AALDH1A1KDM4EBACE1 | |
| SCHEMBL6488383 | 0.86 | MEN1 (0.47) | RAB9AALDH1A1KDM4EBACE1 | |
| SCHEMBL6538543 | 0.82 | BACE1 (0.43) | BACE1 | |
| SCHEMBL6540224 | 0.82 | BACE1 (0.43) | BACE1 | |
| SCHEMBL6538478 | 0.78 | KMT2A (0.47) | ALDH1A1BACE1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | RAB9A 2313/4885ROCK2 1358/4885ALDH1A1 275/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | RAB9A 2825/4885ROCK2 1516/4885ALDH1A1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.